At the 6th World Congress of Cutaneous Lymphoma, a group of world-leading CTCL expert consider what the field will abandon in the next decade.
Neha Mehta-Shah, MD, MSCI
Advertisement
Neha Mehta-Shah, MD, MSCI, is an associate professor of medicine in the Division of Oncology at Washington University in St. Louis.
Articles by Neha Mehta-Shah, MD, MSCI
Neha Mehta-Shah, MD, MSCI explains how rational combinations to overcome CTCL treatment resistance keep running into added toxicity.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
The OncFive: Top Oncology Articles for the Week of 8/9
4
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
5